Clinical Trial Update: Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial comparing bevacizumab plus erlotinib versus erlotinib alone in non-small cell lung cancer with activating EGFR mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: NSCLC | Phase 3 | Status: COMPLETED